|
1
|
Cunningham D, Atkin W, Lenz HJ, et al:
Colorectal cancer. Lancet. 375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McKeown E, Nelson DW, Johnson EK, et al:
Current approaches and challenges for monitoring treatment response
in colon and rectal cancer. J Cancer. 5:31–43. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
da Rocha AB, Lopes RM and Schwartsmann G:
Natural products in anticancer therapy. Curr Opin Pharmacol.
1:364–369. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mann J: Natural products in cancer
chemotherapy: past, present and future. Nat Rev Cancer. 2:143–148.
2002. View
Article : Google Scholar
|
|
5
|
Koehn FE and Carter GT: The evolving role
of natural products in drug discovery. Nat Rev Drug Discov.
4:206–220. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Corson TW and Crews CM: Molecular
understanding and modern application of traditional medicines:
triumphs and trials. Cell. 130:769–774. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang HL, Zhang XH and Chang TH: Effects of
tetrandrine on smooth muscle contraction induced by mediators in
pulmonary hypertension. Acta Pharmacol Sin. 23:1114–1120.
2002.PubMed/NCBI
|
|
8
|
Shen YC, Chou CJ, Chiou WF and Chen CF:
Anti-inflammatory effects of the partially purified extract of
radix Stephaniae tetrandrae: comparative studies of its active
principles tetrandrine and fangchinoline on human polymorphonuclear
leukocyte functions. Mol Pharmacol. 60:1083–1090. 2001.PubMed/NCBI
|
|
9
|
Li SY, Ling LH, Teh BS, Seow WK and Thong
YH: Anti-inflammatory and immunosuppressive properties of the
bis-benzylisoquinolines: in vitro comparisons of tetrandrine and
berbamine. Int J Immunopharmacol. 11:395–401. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang H and Chen X: Tetrandrine ameliorates
cirrhosis and portal hypertension by inhibiting nitric oxide in
cirrhotic rats. J Huazhong Univ Sci Technolog Med Sci. 24:385–388.
3952004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu W, Debeb BG, Lacerda L, Li J and
Woodward WA: Tetrandrine, a compound common in Chinese traditional
medicine, preferentially kills breast cancer tumor initiating cells
(TICs) in vitro. Cancers (Basel). 3:2274–2285. 2011. View Article : Google Scholar
|
|
12
|
Liu W, Zhang J, Ying C, et al: Tetrandrine
combined with gemcitabine and Cisplatin for patients with advanced
non-small cell lung cancer improve efficacy. Int J Biomed Sci.
8:28–35. 2012.PubMed/NCBI
|
|
13
|
He BC, Gao JL, Zhang BQ, et al:
Tetrandrine inhibits Wnt/beta-catenin signaling and suppresses
tumor growth of human colorectal cancer. Mol Pharmacol. 79:211–219.
2011. View Article : Google Scholar :
|
|
14
|
Chen Y, Chen JC and Tseng SH: Effects of
tetrandrine plus radiation on neuroblastoma cells. Anticancer Res.
29:3163–3171. 2009.PubMed/NCBI
|
|
15
|
Wu JM, Chen Y, Chen JC, Lin TY and Tseng
SH: Tetrandrine induces apoptosis and growth suppression of colon
cancer cells in mice. Cancer Lett. 287:187–195. 2010. View Article : Google Scholar
|
|
16
|
Nomura M, Yamazaki R, Takaya M, et al:
Inhibition of tetrandrine on epidermal growth factor-induced cell
transformation and its signal transduction. Anticancer Res.
27:3187–3193. 2007.PubMed/NCBI
|
|
17
|
Meng LH, Zhang H, Hayward L, Takemura H,
Shao RG and Pommier Y: Tetrandrine induces early G1
arrest in human colon carcinoma cells by down-regulating the
activity and inducing the degradation of G1-S-specific
cyclin-dependent kinases and by inducing p53 and
p21Cip1. Cancer Res. 64:9086–9092. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim KS, Seu YB, Baek SH, et al: Induction
of cellular senescence by insulin-like growth factor binding
protein-5 through a p53-dependent mechanism. Mol Biol Cell.
18:4543–4552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vanamala J, Reddivari L, Radhakrishnan S
and Tarver C: Resveratrol suppresses IGF-1 induced human colon
cancer cell proliferation and elevates apoptosis via suppression of
IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer.
10:2382010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ben-Shmuel A, Shvab A, Gavert N, Brabletz
T and Ben-Ze’ev A: Global analysis of L1-transcriptomes identified
IGFBP-2 as a target of ezrin and NF-kappaB signaling that promotes
colon cancer progression. Oncogene. 32:3220–3230. 2013. View Article : Google Scholar
|
|
21
|
Gullu G, Karabulut S and Akkiprik M:
Functional roles and clinical values of insulin-like growth
factor-binding protein-5 in different types of cancers. Chin J
Cancer. 31:266–280. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Butt AJ, Dickson KA, McDougall F and
Baxter RC: Insulin-like growth factor-binding protein-5 inhibits
the growth of human breast cancer cells in vitro and in vivo. J
Biol Chem. 278:29676–29685. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Akkiprik M, Feng Y, Wang H, et al:
Multifunctional roles of insulin-like growth factor binding protein
5 in breast cancer. Breast Cancer Res. 10:2122008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liang PI, Wang YH, Wu TF, et al: IGFBP-5
overexpression as a poor prognostic factor in patients with
urothelial carcinomas of upper urinary tracts and urinary bladder.
J Clin Pathol. 66:573–582. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cesi V, Giuffrida ML, Vitali R, et al:
C/EBP alpha and beta mimic retinoic acid activation of IGFBP-5 in
neuroblastoma cells by a mechanism independent from binding to
their site. Exp Cell Res. 305:179–189. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Su Y, Wagner ER, Luo Q, et al:
Insulin-like growth factor binding protein 5 suppresses tumor
growth and metastasis of human osteosarcoma. Oncogene.
30:3907–3917. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Y, Chen JC and Tseng SH: Tetrandrine
suppresses tumor growth and angiogenesis of gliomas in rats. Int J
Cancer. 124:2260–2269. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
He BC, Chen L, Zuo GW, et al: Synergistic
antitumor effect of the activated PPARgamma and retinoid receptors
on human osteosarcoma. Clin Cancer Res. 16:2235–2245. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ishiyama M, Tominaga H, Shiga M, Sasamoto
K, Ohkura Y and Ueno K: A combined assay of cell viability and in
vitro cytotoxicity with a highly water-soluble tetrazolium salt,
neutral red and crystal violet. Biol Pharm Bull. 19:1518–1520.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He TC, Zhou S, da Costa LT, Yu J, Kinzler
KW and Vogelstein B: A simplified system for generating recombinant
adenoviruses. Proc Natl Acad Sci USA. 95:2509–2514. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Luo J, Deng ZL, Luo X, et al: A protocol
for rapid generation of recombinant adenoviruses using the AdEasy
system. Nat Protoc. 2:1236–1247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Onose J, Imai T, Hasumura M, Cho YM and
Hirose M: A new medium-term rat colon bioassay applying neoplastic
lesions as endpoints for detection of carcinogenesis modifiers -
validation with known modifiers. Cancer Lett. 232:272–278. 2006.
View Article : Google Scholar
|
|
33
|
Zhou L, An N, Haydon RC, et al: Tyrosine
kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin
signaling activity. Cancer Lett. 193:161–170. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fidler MJ, Shersher DD, Borgia JA and
Bonomi P: Targeting the insulin-like growth factor receptor pathway
in lung cancer: problems and pitfalls. Ther Adv Med Oncol. 4:51–60.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Arcaro A: Targeting the insulin-like
growth factor-1 receptor in human cancer. Front Pharmacol.
4:302013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kinzler KW and Vogelstein B: Lessons from
hereditary colorectal cancer. Cell. 87:159–170. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
You Z, Saims D, Chen S, et al: Wnt
signaling promotes oncogenic transformation by inhibiting
c-Myc-induced apoptosis. J Cell Biol. 157:429–440. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gluckman P, Klempt N, Guan J, et al: A
role for IGF-1 in the rescue of CNS neurons following
hypoxic-ischemic injury. Biochem Biophys Res Commun. 182:593–599.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Valentinis B and Baserga R: IGF-I receptor
signalling in transformation and differentiation. Mol Pathol.
54:133–137. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fu P, Thompson JA, Leeding KS and Bach LA:
Insulin-like growth factors induce apoptosis as well as
proliferation in LIM 1215 colon cancer cells. J Cell Biochem.
100:58–68. 2007. View Article : Google Scholar
|
|
41
|
LeRoith D, Werner H, Beitner-Johnson D and
Roberts CT Jr: Molecular and cellular aspects of the insulin-like
growth factor I receptor. Endocr Rev. 16:143–163. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
LeRoith D and Roberts CT Jr: The
insulin-like growth factor system and cancer. Cancer Lett.
195:127–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Weroha SJ and Haluska P: The insulin-like
growth factor system in cancer. Endocrinol Metab Clin North Am.
41:335–350. vi2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang Z, Wang Z, Liang Z, et al: Expression
and clinical significance of IGF-1, IGFBP-3, and IGFBP-7 in serum
and lung cancer tissues from patients with non-small cell lung
cancer. Onco Targets Ther. 6:1437–1444. 2013.PubMed/NCBI
|
|
45
|
Chen D, Siddiq A, Emdad L, et al:
Insulin-like growth factor-binding protein-7 (IGFBP7): a promising
gene therapeutic for hepatocellular carcinoma (HCC). Mol Ther.
21:758–766. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sureshbabu A, Okajima H, Yamanaka D, et
al: IGFBP5 induces cell adhesion, increases cell survival and
inhibits cell migration in MCF-7 human breast cancer cells. J Cell
Sci. 125:1693–1705. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang H, Arun BK, Wang H, et al: IGFBP2 and
IGFBP5 overexpression correlates with the lymph node metastasis in
T1 breast carcinomas. Breast J. 14:261–267. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Luther GA, Lamplot J, Chen X, et al:
IGFBP5 domains exert distinct inhibitory effects on the
tumorigenicity and metastasis of human osteosarcoma. Cancer Lett.
336:222–230. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Femia AP, Luceri C, Toti S, Giannini A,
Dolara P and Caderni G: Gene expression profile and genomic
alterations in colonic tumours induced by 1,2-dimethylhydrazine
(DMH) in rats. BMC Cancer. 10:1942010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Paez D, Gerger A, Zhang W, et al:
Association of common gene variants in the WNT/beta-catenin pathway
with colon cancer recurrence. Pharmacogenomics J. 14:142–150. 2014.
View Article : Google Scholar
|
|
51
|
Kim JH, Liu X, Wang J, et al: Wnt
signaling in bone formation and its therapeutic potential for bone
diseases. Ther Adv Musculoskelet Dis. 5:13–31. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tucker E, Buda A, Janghra B, et al:
Abnormalities of the cadherin-catenin complex in chemically-induced
colo-rectal carcinogenesis. Proc Nutr Soc. 62:229–236. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Imai T, Fukuta K, Hasumura M, et al:
Significance of inflammation-associated regenerative mucosa
characterized by Paneth cell metaplasia and beta-catenin
accumulation for the onset of colorectal carcinogenesis in rats
initiated with 1,2-dimethylhydrazine. Carcinogenesis. 28:2199–2206.
2007. View Article : Google Scholar : PubMed/NCBI
|
